Intelligent Bio Solutions (INBS) Registration filing summary

Company overview and business model

• Operates as a medical technology company developing rapid, non-invasive testing and screening solutions, with a global footprint and headquarters in New York.

• Product portfolio includes the Intelligent Fingerprinting Platform for sweat-based drug screening and a biosensor platform for point-of-care diagnostics.

• Customers span safety-critical industries, rehabilitation, and judicial organizations; commercialized products are available in select international markets.

• Recent 510(k) submission to the FDA for its flagship drug screening system, aiming for US market entry.

Financial performance and metrics

• As of April 10, 2025, market value of outstanding common stock held by non-affiliates is approximately $8.2 million, with 6,811,578 shares outstanding.

• Sold $4.56 million of securities in the prior 12 months under Form S-3 limitations.

• Recent ATM offering raised $47,103 net through sale of 30,592 shares.

• February 2025 public offering raised $3.0 million gross, with all shares sold by the company.

Use of proceeds and capital allocation

• Net proceeds from offerings are intended for working capital and general corporate purposes, including potential acquisitions.